1D09C3, an mAb specific for MHC-II

Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/53599

Full metadata record

DC Field	Value	Language
dc.contributor.author	Zola, H.	-
dc.contributor.author	Beare, A.	-
dc.date.issued	2008	-
dc.identifier.citation	Current Opinion in Molecular Therapeutics, 2008; 10(1):68-74	-
dc.identifier.issn	1464-8431	-
dc.identifier.issn	2040-3445	-
dc.identifier.uri	http://hdl.handle.net/2440/53599	-
dc.description.abstract	GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.	-
dc.description.statementofresponsibility	H Zola and A Beare	-
dc.description.uri	http://www.biomedcentral.com/1464-8431/10/68/abstract	-
dc.language.iso	en	-
dc.publisher	Pharmapress Ltd	-
dc.subject	Animals	-
dc.subject	Humans	-
dc.subject	Antibodies, Monoclonal	-
dc.subject	Histocompatibility Antigens Class II	-
dc.subject	Drug Evaluation, Preclinical	-
dc.subject	Antibody Specificity	-
dc.subject	Structure-Activity Relationship	-
dc.subject	Clinical Trials as Topic	-
dc.subject	Patents as Topic	-
dc.subject	Antibodies, Monoclonal, Humanized	-
dc.subject	Contraindications	-
dc.title	1D09C3, an mAb specific for MHC-II	-
dc.type	Journal article	-
pubs.publication-status	Published	-
Appears in Collections:	Aurora harvest 5 Paediatrics publications

Files in This Item:

There are no files associated with this item.

Show simple item record

Adelaide Research & Scholarship